WTAP-mediated m6A modification promotes drug sensitivity by regulating NR3C1 in prostate cancer
Science China Life Sciences · 2025
DOI: 10.1007/s11427-024-2776-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science China Life Sciences, 2025. Verfasst von Huifeng Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Anatomy, School of Basic Medical Sciences, Guangxi Medical University, Nanning, 530021, China. Hauptthemen laut MEDLINE: Adenosine, Prostatic Neoplasms, Castration-Resistant, RNA Splicing Factors, Receptors, Thyroid Hormone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
The specific mechanisms of N6-methyladenosine (m6A) in castration-resistant prostate cancer (CRPC) remain incompletely understood. Wilms' tumor 1 and pyruvate kinase M2-like protein (WTAP) serve as a major regulatory factor of m6A. However, whether it regulates CRPC through m6A mechanisms is unclear. This research revealed that WTAP stands out as a key regulator among m6A factors, and considerably influences the development and behavior of CRPC. WTAP was downregulated in CRPC. A low WTAP expression predicts poor survival and a high WTAP promotes the flutamide drug sensitivity of CRPC cells. WTAP-modulated m6A modification, which can be recognized by YTHDF2, contributes to the post-transcriptional inactivation of nuclear receptor subfamily 3 group C member 1 (NR3C1). In vitro and in vivo experiments unveiled the key role of NR3C1, a rarely studied oncoprotein, in CRPC. The WTAP/YTHDF2/NR3C1 axis was actively involved in CRPC malignancy and the flutamide drug sensitivity of CRPC cells. The clinical correlation of WTAP, YTHDF2, and NR3C1 was further demonstrated in CRPC tissues and castration-dependent prostate cancer tissues. Our study uncovered a novel molecular mechanism by which the m6A-induced WTAP/YTHDF2/NR3C1 axis promotes CRPC flutamide drug sensitivity. This finding suggests the potential of WTAP as a promising prognostic marker and therapeutic target against flutamide drug sensitivity in CRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Anatomy, School of Basic Medical Sciences, Guangxi Medical University, Nanning, 530021, China.
- Key Laboratory of Human Development and Disease Research, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, 530021, China.
- Collaborative Innovation Centre of Regenerative Medicine and Medical Bio Resource Development and Application Co-constructed by the Province and Ministry, Guangxi Medical University, Nanning, 530021, China.
- Laboratory Animal Center, Guangxi Medical University, Nanning, 530021, China.
- Department of Immunology, Basic Medical College of Guangxi Medical University, Nanning, 530021, China.
- Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nann…
Zitieren
APA
Wang, H., Zhang, D., Ouyang, Y., Li, J., Pang, G., Xie, X., Huang, H., Yan, T., Pang, X., Zhou, Q., Xie, B., Wang, F., An, S., & Hu, Y. (2025). WTAP-mediated m6A modification promotes drug sensitivity by regulating NR3C1 in prostate cancer. Science China Life Sciences. https://doi.org/10.1007/s11427-024-2776-3
Vancouver
Wang H, Zhang D, Ouyang Y, Li J, Pang G, Xie X, et al. WTAP-mediated m6A modification promotes drug sensitivity by regulating NR3C1 in prostate cancer. Science China Life Sciences. 2025. doi:10.1007/s11427-024-2776-3
BibTeX
@article{Wang2025,
author = {Wang, Huifeng and Zhang, Die and Ouyang, Yiqiang and Li, Jinwan and Pang, Guangfu and Xie, Xing and Huang, Hongli and Yan, Tengyue and Pang, Xianwu and Zhou, Qingniao and Xie, Bo and Wang, Fubo and An, Sanqi and Hu, Yanling},
title = {WTAP-mediated m6A modification promotes drug sensitivity by regulating NR3C1 in prostate cancer},
journal = {Science China Life Sciences},
year = {2025},
doi = {10.1007/s11427-024-2776-3}
}
EUVIMED